John Hopkins University

Baltimore, Maryland 21287

15 studies enrolling now · 76 studies all time

What they study most

Ablation, Acute Kidney Injury, Acute Promyelocytic Leukemia, Adenocarcinoma of the Breast, Advanced Solid Tumors, Adverse Drug Event, Allogenic Transplant Patients, Amyotrophic Lateral Sclerosis, Anemia, Arrhythmogenic Right Ventricular Cardiomyopathy, Atrium; Fibrillation, Bladder Cancer

Studies at this site

• Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM — Recruiting now
• Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias — Recruiting now
• ASSESS ALL ALS Study — Recruiting now
• PREVENT ALL ALS Study — Recruiting now
• Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations — Recruiting now
• EXoPERT EMERALD Clinical Study — Recruiting now
• Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) — Recruiting now
• Collaboration for Down Syndrome Progress (CDP) — Recruiting now
• A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE) — Recruiting now
• A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Recruiting now
• HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease — Recruiting now
• Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults — Recruiting now
• Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant — Recruiting now
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Enrolling by invitation
• [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake — Completed
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines — Running, not enrolling
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — Running, not enrolling
• A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain — Completed
• Long-term Safety and Tolerability of BHV-7000 — Enrolling by invitation
• The PROMISE Pediatric Study 6 to 11 Years Old — Completed
• Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis — Running, not enrolling
• A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD — Completed
• Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) — Running, not enrolling
• Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF — Running, not enrolling
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib — Running, not enrolling
• Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer — Running, not enrolling
• Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV — Running, not enrolling
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) — Running, not enrolling
• Comorbid Painful TMD Among Trigeminal Neuralgia — Withdrawn before enrolling
• Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients — Enrolling by invitation
• A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease — Running, not enrolling
• Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria — Enrolling by invitation
• 4 Repeat Tauopathy Neuroimaging Initiative — Completed
• A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines — Completed
• A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. — Completed
• A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis — Completed
• Pilot Randomized Trial With Flecainide in ARVC Patients — Completed
• Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer — Completed
• Simultaneous mRNA COVID-19 and IIV4 Vaccination Study — Completed
• A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia — Paused
• Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression — Completed
• Individualized Response to Vitamin D Treatment Study — Completed
• Study of BHV-3241 in Participants With Multiple System Atrophy — Completed
• Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation — Completed
• Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse — Stopped early
• A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer — Completed
• Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer — Stopped early
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib — Status unconfirmed
• Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) — Stopped early
• Immunotherapy Study for Metastatic Renal Cell Cancer — Completed